Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...
Hosted on MSN12mon
Immuneering (IMRX) Plummets 71% in One Week: Here's WhyThe company’s lead pipeline candidate is IMM-1-104, an investigational RAS medication, which is being evaluated in a phase I/IIa study in patients with advanced solid tumors harboring RAS mutations.
Hosted on MSN1mon
Immuneering and Regeneron partner on lung cancer trialIn other recent news, Immuneering Corp announced significant progress in its ongoing Phase 2a clinical trials involving IMM-1-104, a treatment for advanced RAS-mutant solid tumors. The trials ...
The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback